A5080931906- Esophageal Cancer Research and Treatment
- Esophageal and GI Pathology
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Gastroesophageal reflux and treatments
- Eosinophilic Esophagitis
- Helicobacter pylori-related gastroenterology studies
- Gastrointestinal Tumor Research and Treatment
- Advanced Chemical Sensor Technologies
- Analytical Chemistry and Chromatography
- Cancer-related gene regulation
- Metabolomics and Mass Spectrometry Studies
- Pancreatic and Hepatic Oncology Research
- Global Cancer Incidence and Screening
- Colorectal Cancer Screening and Detection
- Cancer survivorship and care
- Biomedical Ethics and Regulation
- Biomedical and Engineering Education
- Gastrointestinal disorders and treatments
- Women's cancer prevention and management
- Quality and Safety in Healthcare
- Gastrointestinal Bleeding Diagnosis and Treatment
- Cancer Cells and Metastasis
- Tracheal and airway disorders
- Family Support in Illness
Hutchison/MRC Research Centre
2013-2023
University of Cambridge
2015-2023
Cancer Research UK Cambridge Center
2022-2023
MRC Cancer Unit
2013-2022
Medical Research Council
2013
Background Barrett's esophagus (BE) is a commonly undiagnosed condition that predisposes to esophageal adenocarcinoma. Routine endoscopic screening for BE not recommended because of the burden this would impose on health care system. The objective study was determine whether novel approach using minimally invasive cell sampling device, Cytosponge, coupled with immunohistochemical staining biomarker Trefoil Factor 3 (TFF3), could be used identify patients who warrant endoscopy diagnose BE....
Treatment of dysplastic Barrett's oesophagus prevents progression to adenocarcinoma; however, the optimal diagnostic strategy for is unclear. The Cytosponge-trefoil factor 3 (TFF3) a non-endoscopic test oesophagus. aim this study was investigate whether offering patients on medication gastro-oesophageal reflux would increase detection compared with standard management.
Objective Barrett’s oesophagus is a premalignant condition that occurs in the context of gastro-oesophageal reflux. However, most cases are undiagnosed because reliance on endoscopy. We have developed non-endoscopic tool: Cytosponge, which when combined with trefoil factor 3 immunohistochemistry, can diagnose oesophagus. investigated whether quantitative methylation test not reliant histopathological analysis could be used to Design Differentially methylated genes between and normal squamous...
Aims Reflux symptoms are highly prevalent and non‐specific; hence, in the absence of alarm symptoms, endoscopy referral decisions challenging. This study evaluated whether a non‐endoscopic Cytosponge could detect benign oesophageal pathologies thus have future potential triaging patients with persistent symptoms. Methods results Two complementary cohorts were recruited: (i) reflux no prior ( n = 409), (ii) referred for 411). All investigated using endoscopy. Significant epithelial...
Early detection of oesophageal cancer improves outcomes; however, the optimal strategy for identifying patients at increased risk from pre-cancerous lesion Barrett's oesophagus (BE) is not clear. The Cytosponge, a novel non-endoscopic sponge device, combined with biomarker Trefoil Factor 3 (TFF3) has been tested in four clinical studies. It was found to be safe, accurate and acceptable patients. aim BEST3 trial evaluate if offer Cytosponge-TFF3 test primary care on long term acid...
INTRODUCTION: Liver cirrhosis and its complication — hepatocellular carcinoma (HCC) have been associated with increased exhaled limonene. It is currently unclear whether this increase more strongly the presence of HCC or severity liver dysfunction. METHODS: We compared breath 40 controls, 32 cirrhotic patients, 12 patients using Breath Biopsy platform. samples were analyzed by thermal desorption–gas chromatography–mass spectrometry. Limonene levels between groups correlated to bilirubin,...
Background and AimsThe prevalence of chronic liver disease in adults exceeds 30% some countries there is significant interest developing tests treatments to help control progression reduce healthcare burden. Breath a rich sampling matrix that offers non-invasive solutions suitable for early-stage detection monitoring. Having previously investigated targeted analysis single biomarker, here we multiparametric approach breath testing would provide more robust reliable results clinical use.
Esophageal sponge cytology is an endoscopy alternative well accepted by patients with extensive data for accuracy in the context of adenocarcinoma. Few studies have assessed its feasibility asymptomatic community members, and fewer still East Africa, where esophageal squamous cell carcinoma (ESCC) rates are high. We aimed to assess a capsule-based diagnosis dysplasia (ESD), ESCC precursor, which may benefit epidemiological early detection research. collected Cytosponge collections 102 adults...
Objectives The BEST3 trial demonstrated the efficacy and safety of Cytosponge-trefoil factor 3, a cell collection device coupled with biomarker trefoil as tool for detecting Barrett’s oesophagus, precursor oesophageal adenocarcinoma (OAC), in primary care. In this nested study, our aim was to understand patient experiences. Design Mixed-methods using questionnaires (including Inventory Assess Patient Satisfaction, Spielberger State-Trait Anxiety Inventory-6 two-item perceived risk)...
BackgroundEffective surveillance strategies are required for patients diagnosed with oesophageal squamous cell carcinoma (OSCC) or adenocarcinoma (OAC) whom chemoradiotherapy (CRT) is used as a potentially-curative, organ-sparing, alternative to surgery. In this study, we evaluated the safety, acceptability and tolerability of non-endoscopic immunocytological device (the Cytosponge™) assess treatment response following CRT.MethodsThis multicentre, single-arm feasibility trial took place in...
Cytosponge is a novel technology for oesophageal pathology diagnosis. Uses include diagnosis of Barrett's oesophagus and as triage tool to prioritise upper gastrointestinal endoscopy. Patient experience key component quality care. Previous work has developed endoscopy patient-reported measures. An appropriate measure patient required. The aim this was describe the Cytosponge. Individuals aged 18 years or over, who had undergone from September 2020 March 2021, were invited participate in...
Abstract Background The Cytosponge is a cell-collection device, which, coupled with test for trefoil factor 3 (TFF3), can be used to diagnose Barrett’s oesophagus, precursor condition oesophageal adenocarcinoma. BEST3, large pragmatic, randomised, controlled trial, investigated whether offering the Cytosponge-TFF3 would increase detection of Barrett’s. Overall, participants reported mostly positive experiences. This study reports factors associated least experience. Methods Patient...
Abstract Continual evolution of cancer makes it challenging to predict clinical outcomes. Highly varied and unpredictable patient outcomes in esophageal adenocarcinoma (EAC) prompted us question the pattern timing metastatic spread. Whole genome sequencing phylogenetic analysis 396 samples across 18 EAC cases demonstrated a stellate on trees 90% cases. The age-dependent trinucleotide signature, which can serve as molecular clock, was absent or reduced branches beyond trunk most...
Continual evolution of cancer on a microscopic scale makes accurate clinical assessment challenging. The highly varied and unpredictable patient outcomes in esophageal adenocarcinoma (EAC) prompted us to question conventional modes metastatic spread. Whole genome sequencing phylogenetic analysis 396 samples across 18 EAC cases demonstrated contemporaneous polyclonal seeding from the primary multiple disparate sites at single time-point 90% cases- so-called clonal diaspora. age-dependent...